Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17621571 | 0.79 | PIK3CD (0.58) | PIK3CD | |
| SCHEMBL17544674 | 0.78 | PIK3CD (0.47) | PIK3CD | |
| SCHEMBL783215 | 0.77 | PIK3CD (0.64) | PIK3CDNAAA | |
| SCHEMBL17616464 | 0.75 | PIK3CD (0.57) | PIK3CD | |
| SCHEMBL24926047 | 0.74 | PIK3CD (0.60) | PIK3CDNAAA | |
| SCHEMBL20467217 | 0.74 | PIK3CD (0.60) | PIK3CDNAAA | |
| SCHEMBL14459655 | 0.71 | PIK3CD (0.56) | PIK3CDNAAA | |
| SCHEMBL19701912 | 0.71 | PIK3CD (1.00) | PIK3CDNAAA | |
| SCHEMBL22044606 | 0.71 | PIK3CD (0.56) | PIK3CDNAAA | |
| SCHEMBL19788789 | 0.71 | PIK3CD (0.56) | PIK3CDNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-A1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2023-03-08 | — | — | EP | disclosed |
| EP-3186239-B1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3186239-A1 | ANTIRETROVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-8883778-B2 | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883778-B2 | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2448928-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2448928-B1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20120232050-A1 | Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232050-A1 | Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232050-A1 | Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2448928-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002910-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002910-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | PIK3CD 1566/4885NAAA 4013/4885 |
| US-20120232050-A1 | Cyclic Inhibitors of 11 beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD3B1, HSD11B2 | PIK3CD 863/4885NAAA 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.